156 related articles for article (PubMed ID: 31719064)
21. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and outcome of post-transfusion hepatitis C acquired at different ages and detected in look-back screening.
Millbourn C; Psaros Einberg A; Lindh G; Hökeberg I; Fischler B; Lindahl K
Scand J Gastroenterol; 2018; 53(7):870-875. PubMed ID: 29909701
[TBL] [Abstract][Full Text] [Related]
23. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
24. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
26. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden.
Hofmann JN; Törner A; Chow WH; Ye W; Purdue MP; Duberg AS
Eur J Cancer Prev; 2011 Jul; 20(4):326-30. PubMed ID: 21386707
[TBL] [Abstract][Full Text] [Related]
27. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007.
Thein HH; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ
J Viral Hepat; 2011 Jul; 18(7):e232-41. PubMed ID: 21692938
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
[TBL] [Abstract][Full Text] [Related]
29. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
32. Oncologic Implications of Chronic Hepatitis C Virus Infection.
Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
[TBL] [Abstract][Full Text] [Related]
33. Primary liver cancer incidence-rates related to hepatitis-C virus infection: a correlational study in Osaka, Japan.
Tanaka H; Hiyama T; Okubo Y; Kitada A; Fujimoto I
Cancer Causes Control; 1994 Jan; 5(1):61-5. PubMed ID: 7510133
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
35. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
36. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
37. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C; Lorenzini P; Puoti M; Lichtner M; Lapadula G; Di Giambenedetto S; Antinori A; Madeddu G; Cozzi-Lepri A; d'Arminio Monforte A; De Luca A;
PLoS One; 2015; 10(12):e0140877. PubMed ID: 26640953
[TBL] [Abstract][Full Text] [Related]
39. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study.
Bellentani S; Pozzato G; Saccoccio G; Crovatto M; Crocè LS; Mazzoran L; Masutti F; Cristianini G; Tiribelli C
Gut; 1999 Jun; 44(6):874-80. PubMed ID: 10323892
[TBL] [Abstract][Full Text] [Related]
40. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
